Literature DB >> 9472623

Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter.

S Günther1, N Piwon, H Will.   

Abstract

Hepatitis B virus (HBV) isolates with A-1762 to T and G-1764 to A mutations in the core promoter have been associated with active hepatitis, severe liver disease following liver transplantation, hepatocellular carcinoma and acute fulminant courses--in the latter case combined with a C-1653 to T mutation. In this study, a mutant core promoter region containing the T-1653, T-1762 and A-1764 mutations was placed into the context of a wild-type HBV genome and analysed by transfection. The mutations reduced the level of pre-C mRNA (by 55%) and e-antigen secretion. In contrast, no significant effects on the levels of pregenome/C and pre-S/S mRNAs, intracellular core, polymerase, and pre-S /S2 proteins and secreted S-antigen were observed. The amount of progeny virus DNA in the cells and in the culture medium was increased marginally, if at all.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9472623     DOI: 10.1099/0022-1317-79-2-375

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  30 in total

1.  Early mutation of precore (A1896) region prior to core promoter region mutation leads to decrease of HBV replication and remission of hepatic inflammation.

Authors:  Y Karino; J Toyota; T Sato; T Ohmura; K Yamazaki; T Suga; K Nakamura; M Sugawara; T Matsushima; K Hino
Journal:  Dig Dis Sci       Date:  2000-11       Impact factor: 3.199

Review 2.  Update of research and management of hepatitis B.

Authors:  Takeshi Okanoue; Masahito Minami
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 3.  X region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 4.  Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

Authors:  Catherine Mn Croagh; Paul V Desmond; Sally J Bell
Journal:  World J Hepatol       Date:  2015-03-27

5.  Critical roles of nuclear receptor response elements in replication of hepatitis B virus.

Authors:  X Yu; J E Mertz
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan.

Authors:  Chien-Hung Chen; Chuan-Mo Lee; Sheng-Nan Lu; Chi-Sin Changchien; Hock-Liew Eng; Chao-Min Huang; Jing-Houng Wang; Chao-Hung Hung; Tsung-Hui Hu
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

7.  Genetic variations of hepatitis B virus and serum aflatoxin-lysine adduct on high risk of hepatocellular carcinoma in Southern Guangxi, China.

Authors:  Li Xu; Guoqing Qian; Lili Tang; Jianjia Su; Jia-Sheng Wang
Journal:  J Hepatol       Date:  2010-06-20       Impact factor: 25.083

8.  Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture.

Authors:  H Tang; A K Raney; A McLachlan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Regulation of hepatitis B virus core promoter by transcription factors HNF1 and HNF4 and the viral X protein.

Authors:  Yanyan Zheng; Jie Li; Jing-hsiung Ou
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.

Authors:  Noboru Shinkai; Yasuhito Tanaka; Kiyoaki Ito; Motokazu Mukaide; Izumi Hasegawa; Yasuhiro Asahina; Namiki Izumi; Hiroshi Yatsuhashi; Etsuro Orito; Takashi Joh; Masashi Mizokami
Journal:  J Clin Microbiol       Date:  2007-07-25       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.